Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ACT-333679

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundMyofibroblasts contribute to fibrosis through the overproduction of extracellular matrix (ECM) proteins, primarily type… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Prostacyclin (PGI2) receptor (IP receptor) agonists, which are indicated for the treatment of pulmonary arterial hypertension… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
PURPOSE Selexipag is a new orally available nonprostanoid prostacyclin receptor agonist for the treatment of pulmonary arterial… Expand
Is this relevant?
2015
2015
Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production… Expand
Is this relevant?
2015
2015
PurposeTargeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Prostacyclin receptor (IP receptor) agonists, which are used in the treatment of pulmonary arterial hypertension (PAH), increase… Expand
Is this relevant?
2014
2014
Objective: The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
The prostacyclin (IP) receptor agonists, treprostinil, iloprost and the selexipag metabolite, MRE-269 (ACT-333679) were evaluated… Expand
Is this relevant?
2012
2012
{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2010
2010
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 5
  • figure 6
Is this relevant?